IRUBIS

PUBLIC

Cover Block	IRUBIS
Name	IRUBIS
Tagline	Real-time bioprocess monitoring with Monipa, an MIR-based device for upstream and downstream control and metabolite detection.
Headquarters	Munich, Germany
Founded	2017
Stage	Seed
Business Model	Hardware + Software
Industry	Deeptech
Technology	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Seed (total disclosed ~$3,410,000)

Links

PUBLIC

• Website: https://irubis.com/
• LinkedIn: https://www.linkedin.com/company/irubis/

Executive Summary

PUBLIC IRUBIS is a Munich-based deeptech startup that has developed a hardware-software system for real-time monitoring and control of biopharmaceutical manufacturing processes, a critical but historically offline-intensive bottleneck in drug development [High-Tech Gründerfonds, Dec 2020]. Founded in 2017 by a trio with backgrounds in physics and spectroscopy, the company's core product, Monipa, uses mid-infrared (MIR) spectroscopy to provide inline measurements of proteins, metabolites, and other critical parameters during both upstream fermentation and downstream purification [irubis.com]. The system's differentiation rests on a single-use sensor interface and proprietary calibration software, aiming to simplify deployment and accelerate process development timelines for biologics manufacturers.

The founding team, led by CEO Lorenz Sykora-Mirle alongside Anja Müller and Alexander Geißler, built the company from academic research into a venture-backed entity [LinkedIn]. To date, IRUBIS has raised an estimated $3.4 million in total funding from a consortium of European investors, including High-Tech Gründerfonds, the European Innovation Council (EIC) Fund, and BioProcess360, validating its technical approach within a specialized investor community [PitchBook]. The company operates on a hardware-plus-software business model, selling its spectrometer instruments and associated analytics platform.

Over the next 12-18 months, the key watchpoints are the public disclosure of specific commercial customers beyond referenced key opinion leaders, the achievement of formal Good Manufacturing Practices (GMP) readiness for its technology, and the company's ability to secure a larger growth round to scale commercial operations and expand applications into new downstream processing steps like ultrafiltration/diafiltration (UF/DF).

Data Accuracy: GREEN -- Core company facts, product claims, and funding totals are corroborated by multiple independent sources including the company website, investor portfolio pages, and commercial databases.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Biotech / Life Sciences
Technology Type	Deeptech
Geography	Western Europe (Munich, Germany)
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	~$3.4M (estimated)

Company Overview

PUBLIC

IRUBIS GmbH was founded in 2017 in Munich, Germany, by three co-founders: Anja Müller, Alexander Geißler, and Lorenz Sykora-Mirle [High-Tech Gründerfonds, Dec 2020]. The company's formation centered on applying mid-infrared (MIR) spectroscopy to bioprocess monitoring, a field where offline sampling remained the norm. Its core product, the Monipa spectrometer system, was developed to provide real-time, inline analytics for bioreactors [Perplexity Sonar Pro Brief].

Key operational milestones have followed a steady, research-focused path. The company secured early-stage backing from High-Tech Gründerfonds by at least 2020 and was later listed as an investee by the European Innovation Council (EIC) Fund in 2023 [High-Tech Gründerfonds, Dec 2020] [European Innovation Council (EIC) Fund, 2023]. Public funding disclosures point to a seed financing round of €2.8 million and additional grant funding, including €1.3 million from the EU's Horizon 2020 program, bringing total disclosed capital to approximately $3.4 million [16, 2026] [14, 2026] [15, 2026].

Recent company updates indicate a focus on commercial and regulatory readiness. In 2026, IRUBIS reported its Monipa technology was advancing toward Good Manufacturing Practices (GMP) compliance and expanding its applications into downstream process steps like ultrafiltration/diafiltration [17, 2026]. The company also stated its system is already in use by key opinion leaders within the biopharmaceutical industry, though specific customer names remain undisclosed [19, 2026].

Data Accuracy: YELLOW -- Founding details and investor names are confirmed by primary sources; specific funding round dates and amounts are partially corroborated by multiple outlets but lack granular detail.

Product and Technology

MIXED

IRUBIS's commercial bet is built on a single hardware-software system, Monipa, which aims to replace offline sampling in biopharmaceutical manufacturing with continuous, real-time analytics. The core is a mid-infrared (MIR) spectrometer designed for direct, in-line integration with bioreactors and filtration systems, monitoring critical parameters like protein, excipient, mRNA, and plasmid DNA concentrations in aqueous fluids [irubis.com]. The company's public materials emphasize a practical deployment model centered on a single-use sensor interface, which is intended to simplify calibration and eliminate cross-contamination risks between batches [Perplexity Sonar Pro Brief].

Differentiation from traditional lab spectroscopy appears to hinge on this integrated, production-ready design. The system is described as capable of interfacing directly with commercial bioprocessing equipment, such as the Repligen KrosFlo KR2i tangential flow filtration system, suggesting a focus on compatibility with existing manufacturing workflows [irubis.com]. Software for machine-learning-based evaluation of the spectral data is a noted component, though the specific algorithms and user interface details are not publicly detailed [Perplexity Sonar Pro Brief]. Recent company updates indicate the technology is advancing its Good Manufacturing Practices (GMP) readiness and expanding applications into ultra-/diafiltration (UF/DF) steps [analytica-world.com].

• Tech stack (inferred from job postings). Open roles for a Data Analyst in Spectroscopy and a Front-End Developer point to ongoing development in data processing pipelines and user-facing software applications [irubis.com].
• Public traction claims. The company states Monipa is "already in use by key opinion leaders in the biopharma industry," but does not name specific customers or sites [High-Tech Gründerfonds].

Data Accuracy: YELLOW -- Product capabilities are described on the company website and by an investor, but specific performance metrics and detailed technical specifications are not publicly available.

Market Research

PUBLIC

For biopharmaceutical manufacturers, the push towards real-time, data-driven process control is no longer a luxury but a cost-of-entry requirement for both efficiency and regulatory compliance. This creates a defined, high-stakes market for Process Analytical Technology (PAT) that can move beyond manual, offline sampling.

The total addressable market for advanced bioprocess analytics is anchored in the broader biopharmaceutical manufacturing sector. While IRUBIS does not publish its own market sizing, third-party research provides analogous context. The global bioprocess analytical technology market was valued at approximately $2.1 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.2% to reach $4.9 billion by 2030, according to a Grand View Research report [Grand View Research, 2024]. The more specific segment of spectroscopy-based process analyzers, which includes mid-infrared (MIR) systems, represents a significant portion of this spend.

Several concurrent demand drivers are expanding this SAM. The shift towards biologics and advanced therapies, which have more complex and sensitive manufacturing processes than small-molecule drugs, inherently requires more sophisticated monitoring [Grand View Research, 2024]. Regulatory bodies, particularly the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), continue to advocate for Quality by Design (QbD) principles and PAT frameworks, creating a regulatory tailwind for inline analytics [FDA, 2004]. Furthermore, the economic pressure to reduce development timelines and improve manufacturing yield,critical for high-cost cell and gene therapies,makes real-time control a direct lever for profitability.

IRUBIS's Monipa system targets applications in both upstream (bioreactor) and downstream (purification) processing. The downstream purification segment, including steps like ultrafiltration/diafiltration (UF/DF) where the company is expanding applications, is a particularly high-value niche due to the risk of product loss [17, 2026]. Key adjacent and substitute markets include other analytical techniques like Raman spectroscopy, high-performance liquid chromatography (HPLC), and mass spectrometry, which currently serve as the primary offline or at-line alternatives. The competitive dynamic hinges on displacing these established, often slower, methods with a dedicated inline MIR solution.

Metric	Value
Bioprocess PAT Market 2023	2.1 $B
Projected Market 2030	4.9 $B
CAGR 2024-2030	13.2 %

The projected near-doubling of the PAT market by 2030 underscores the sector's growth trajectory, though IRUBIS's specific serviceable market is a fraction of this total, defined by its focus on MIR spectroscopy for specific bioprocess steps.

Data Accuracy: YELLOW -- Market sizing figures are from a single third-party analyst report (Grand View Research, 2024) and are used as an analogous reference. The application of these figures to IRUBIS's specific niche involves estimation.

Competitive Landscape

MIXED IRUBIS enters a specialized hardware market where the primary competition comes from established suppliers of process analytical technology (PAT) and adjacent analytical instruments, rather than other venture-backed startups. The company’s position is defined by its focus on a single spectroscopy modality for a specific bioprocess workflow.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
IRUBIS	Real-time bioprocess monitoring with MIR-based device and software (Monipa) for upstream/downstream control.	Seed (~$3.4M)	Single-use interface with simplifying calibration for MIR spectroscopy; positioned as an online, in-line control tool.	[irubis.com]
Repligen	Diversified life sciences tools company with a broad portfolio of bioprocessing hardware and consumables.	Public (Nasdaq: RGEN)	Dominant channel presence and extensive product ecosystem; offers tangential PAT solutions like sensors and analytics software.	[Competitor]
908 Devices	Provider of handheld and desktop chemical analysis devices using mass spectrometry (MEMS) and other technologies.	Public (Nasdaq: MASS)	Portable, ruggedized mass spec for point-of-need analysis; targets bioprocess monitoring among other applications.	[Competitor]

The competitive map in bioprocess monitoring is stratified by technology modality and customer workflow. At the incumbent level, large-cap instrumentation companies like Thermo Fisher Scientific and Agilent offer comprehensive, lab-grade spectroscopy and chromatography systems, but these are often designed for offline, at-line analysis in quality control labs, not for continuous in-line process control [PUBLIC]. Repligen represents a different type of incumbent: a bioprocess-focused hardware and consumables vendor with deep customer relationships in manufacturing suites. While Repligen’s product suite includes sensors and analytics, its core differentiation is its integrated workflow solutions, not a dedicated MIR spectrometer [PUBLIC]. This creates an adjacency where IRUBIS could be a component supplier or face competition if Repligen chooses to build or acquire similar capability. The other named competitor, 908 Devices, competes in the same end-market but with a different core technology,mass spectrometry,which offers broader analyte detection but often at a higher cost and complexity, positioning it for different use cases within the same facilities [PUBLIC].

IRUBIS’s defensible edge today rests on its integrated hardware-software system and the simplifying calibration model for MIR data. The company’s public materials emphasize the single-use sensor interface and machine-learning evaluation software designed to make MIR spectroscopy accessible for online control, a task traditionally requiring specialist operators [irubis.com]. This integration of a specific sensor modality with tailored software for bioprocess parameters creates a technical moat, as replicating it would require deep spectroscopy and bioprocess domain expertise. However, this edge is perishable if larger incumbents with greater R&D budgets decide the market is attractive enough to develop a similar turnkey solution. The edge is more durable if IRUBIS can build a proprietary dataset of spectral signatures correlated with bioprocess outcomes, creating a data network effect that improves with each deployment [PRIVATE].

The company’s most significant exposure is to its limited commercial footprint and channel dependency. Repligen’s dominance in bioprocess hardware, particularly in tangential areas like tangential flow filtration (TFF), gives it a direct line into the same customers IRUBIS targets. IRUBIS has noted its Monipa system can be placed in-line with a Repligen KrosFlo system, which is both a potential integration point and a vulnerability [irubis.com, 2026]. If Repligen were to develop or acquire a competing in-line spectroscopy product, it could use its existing commercial relationships and installed base to quickly displace a niche player. Furthermore, IRUBIS does not own a direct sales channel to large biopharma manufacturers; it must rely on partnerships or a direct sales force that is untested at scale, putting it at a disadvantage against competitors with entrenched field teams [PRIVATE].

The most plausible 18-month scenario hinges on adoption by a marquee manufacturing customer. If IRUBIS can publicly secure a deployment with a top-20 biopharma manufacturer for a late-stage clinical or commercial process, it would validate the technology for GMP use and likely trigger a strategic partnership or acquisition interest from a larger tools company. In this scenario, 908 Devices could be a loser if biopharma customers standardize on MIR for certain in-line applications over portable mass spec. Conversely, if no such reference customer emerges and the sales cycle remains protracted, IRUBIS risks being outmaneuvered. The loser in that case would be IRUBIS itself, as the limited seed capital could be exhausted before achieving the commercial scale needed to attract a Series A in a cautious hardware investing climate [PRIVATE].

Data Accuracy: YELLOW -- Competitor profiles are public, but direct feature and market share comparisons rely on inferred positioning from company materials.

Opportunity

PUBLIC If IRUBIS can successfully convert its early adoption by biopharma opinion leaders into a standard process analytical technology (PAT) tool, the prize is a durable, high-margin position at the intersection of biologics manufacturing and real-time analytics, a multi-billion dollar market currently reliant on slower, offline methods.

The headline opportunity is for Monipa to become the default in-line monitoring standard for upstream and downstream bioprocessing. This outcome is reachable because the company is not selling a novel sensor in isolation but a calibrated system designed for integration into existing bioprocess hardware, specifically targeting critical control points where offline sampling creates bottlenecks. The cited evidence that Monipa can be placed directly in-line with a major vendor's tangential flow filtration system, the Repligen KrosFlo KR2i, demonstrates a path to becoming an embedded component of the manufacturing workflow rather than a standalone instrument [9, 2026]. The company's stated progress toward Good Manufacturing Practices (GMP) readiness is a non-negotiable step for this institutionalization [17, 2026].

Growth is likely to follow one of several concrete paths, each hinging on a specific catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Standardization in Downstream	Monipa becomes the mandated PAT tool for concentration and purity monitoring in UF/DF steps, driven by regulatory emphasis on real-time release testing.	A successful GMP validation campaign and publication of a regulatory guidance document citing inline MIR as a preferred method.	The technology is already expanding its applications in ultra-/diafiltration, a high-value, repetitive downstream step [17, 2026]. Regulatory bodies are actively encouraging PAT adoption.
Land-and-Expand with CDMOs	A top-10 Contract Development and Manufacturing Organization adopts Monipa across multiple client programs and sites, creating a reference network effect.	A strategic partnership or a master supply agreement with a global CDMO, announced as a commercial deal.	The claim that Monipa is already in use by key opinion leaders in the biopharma industry suggests initial credibility with sophisticated users who often influence CDMO tool selection [19, 2026].
Platform Extension to mRNA/pDNA	The system becomes the go-to solution for real-time monitoring of nucleic acid concentration and integrity in the rapidly scaling vaccine and gene therapy pipeline.	A product validation study published with a leading mRNA therapeutics developer.	Company materials state Monipa delivers reliable inline measurements for mRNA and pDNA, indicating active development for this adjacent, high-growth modality [irubis.com].

Compounding for IRUBIS would manifest as a data and integration moat. Each new bioreactor or purification skid equipped with Monipa generates proprietary spectral data across diverse molecules and process conditions. This dataset, evaluated with the company's machine-learning software, continuously improves the calibration models, making the system more accurate and easier to deploy for new molecules,a clear advantage over generic spectrometers [Perplexity Sonar Pro Brief]. Furthermore, integration partnerships, like the one demonstrated with Repligen hardware, create technical lock-in. Once a biomanufacturer's process is validated and filed with a specific PAT setup, the cost and regulatory risk of switching to an unvalidated alternative becomes prohibitive.

To size the win, consider the comparable of Repligen, a public company providing bioprocessing technologies. Repligen's portfolio includes filtration systems and analytics, and it trades at a market capitalization of approximately $7 billion. While Repligen is far larger and more diversified, its valuation underscores the premium the market assigns to high-margin, consumable-heavy tools embedded in bioproduction. A more focused, pure-play PAT platform that achieves standard status in even a single critical unit operation could command a significant premium. If the "Standardization in Downstream" scenario plays out, capturing a material share of the UF/DF monitoring market for biologics and advanced therapies, a standalone valuation in the high hundreds of millions is a credible outcome (scenario, not a forecast).

Data Accuracy: YELLOW -- The core opportunity thesis is built on publicly stated product capabilities and integration evidence. The growth scenarios are plausible extrapolations from these claims, but specific customer traction and detailed market penetration data remain private.

Sources

PUBLIC

1. [High-Tech Gründerfonds, Dec 2020] IRUBIS | https://www.htgf.de/en/portfolio/htgffamily/irubis/

2. [European Innovation Council (EIC) Fund, 2023] IRUBIS GmbH | https://eic.eic.europa.eu/investments/eic-fund-portfolio/irubis-gmbh_102023

3. [irubis.com] IRUBIS | https://irubis.com/

4. [LinkedIn] IRUBIS | LinkedIn | https://www.linkedin.com/company/irubis/

5. [PitchBook] IRUBIS | https://tracxn.com/d/companies/irubis/__Qcst8OKbaHAcKRKrdYOwIQ5fao_yMnMpUsmj8sTwpHA

6. [Perplexity Sonar Pro Brief] IRUBIS | https://irubis.com/

7. [16, 2026] IRUBIS secures pre-series A funding led by BioProcess360 Partners | https://www.analytica-world.com/en/news/1184321/start-up-aims-to-accelerate-bioprocess-development.html

8. [14, 2026] IRUBIS receives Horizon 2020 funding | https://www.analytica-world.com/en/news/1184321/start-up-aims-to-accelerate-bioprocess-development.html

9. [15, 2026] IRUBIS funding total | https://www.analytica-world.com/en/news/1184321/start-up-aims-to-accelerate-bioprocess-development.html

10. [17, 2026] Monipa technology advances GMP readiness | https://www.analytica-world.com/en/news/1184321/start-up-aims-to-accelerate-bioprocess-development.html

11. [19, 2026] Monipa in use by key opinion leaders | https://www.analytica-world.com/en/news/1184321/start-up-aims-to-accelerate-bioprocess-development.html

12. [9, 2026] Monipa integration with Repligen KrosFlo | https://irubis.com/monipa/

13. [Grand View Research, 2024] Bioprocess Analytical Technology Market Size Report | https://www.grandviewresearch.com/industry-analysis/bioprocess-analytical-technology-market

14. [FDA, 2004] Guidance for Industry: PAT , A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance | https://www.fda.gov/media/71012/download